News

In this episode, Greenberg and Bennett provide some perspective on the fluidity of MOGAD diagnosis and how it could potentially change over time as more is understood about neuroimmune disorders. [WATCH TIME: 5 minutes]

A 28-year-old patient initially diagnosed with Guillain–Barré Syndrome presented with multiple cranial neuropathies and was later rediagnosed with chronic inflammatory demyelinating polyneuropathy.

In this segment, the duo of neurologists provided a number of informative considerations treating clinicians should take when diagnosing MOGAD, emphasizing careful testing and interpretation of data in this complex process. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The consultant neurologist at Imperial College Healthcare Trust discussed how smoldering MS challenges traditional views of disease progression, seeking combined therapies targeting both inflammatory activity and mechanisms driving smoldering-associated worsening. [WATCH TIME: 4 minutes]

A recent study suggests that patients with chronic inflammatory demyelinating polyneuropathy lacking nerve conduction study evidence of demyelination can still respond positively to immunomodulatory therapies.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on non-relapsing secondary progressive multiple sclerosis.

In the phase 1 trial, the 2.5 mg dose of ORX750 significantly improved wakefulness, restoring normal sleep latency to 32 minutes compared to placebo.

The phase 1 study of RAG-17 in patients SOD1-ALS revealed safety, tolerability, and early clinical benefits across all dose levels.

Neurology News Network. for the week ending September 14, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 13, 2024.

Approved based on the phase 3 OCARINA II trial, the new subcutaneous formulation offers patients with multiple sclerosis more flexibility to choose treatment options that suit their individual needs.

A recent study showed that an increase in anti-hepatitis E virus seroprevalence in patients with chronic inflammatory demyelinating polyneuropathy was not a consequence of intravenous immunoglobulin therapy.

VO659 was considered safe and well tolerated, with treated patients showing no sustained increase in neurofilament light protein through day 85 of treatment.

The consultant neurologist at Imperial College Healthcare Trust highlighted the importance of acknowledging smoldering multiple sclerosis, urging a shift in therapeutic focus beyond relapses and advocating for a new approach to disease management. [WATCH TIME: 5 minutes]

New findings from the CAMPSIITE trial highlight that RGX-121 gene therapy significantly reduces cerebrospinal fluid biomarkers, suggesting its potential as a first treatment for Hunter syndrome.

Treatment with STK-001, an antisense oligonucleotide, resulted in significant reductions in seizure activity at the 3- and 6-month timepoints after last dose.

BB-031 aims to expand the population eligible for acute revascularization therapy by reopening blocked arteries beyond the traditional therapeutic window, potentially increasing eligible AIS patients by nearly 50%.

The disease area stronghold leader in neurodegeneration at Johnson & Johnson provided insight on the importance of the Global Neurodegeneration Proteomics Consortium, illustrated in several presentations at the recently concluded AAIC 2024. [WATCH TIME: 7 minutes]

Results revealed that adjunctive treatment with intravenous argatroban or eptifibatide was associated with increased mortality in acute ischemic stroke treated with intravenous thrombolysis.

Treatment with Lu AG09222 as a migraine preventive was safe, with common adverse events that included COVID-19, nasopharyngitis, and fatigue.

Michael McDermott, MD, chief medical executive of Baptist Health Miami Neuroscience Institute, provided commentary on the early stages of a recently designed protective surfing helmet.

STK-001 (zorevunersen), an investigational therapy, shows promising results in reducing seizures and improving cognition in patients with Dravet syndrome, offering potential beyond current anti-seizure medications.

Across 4 trials with over 4800 patients, rimegepant demonstrated superior pain and symptom relief 2 hours post-dose, with fewer requiring rescue medication.

Recent data and conversations with experts highlighted the increasing concern of Long COVID’s impact on the brain in patients who have been previously infected with the virus.

The postdoctoral researcher at Amsterdam University Medical Center talked about a tool that helps assess the likelihood of transitioning to secondary progressive multiple sclerosis, allowing clinicians to make informed treatment decisions in a timely manner.

The consultant neurologist at Imperial College Healthcare Trust talked about how smoldering disease in multiple sclerosis encompasses disease progression independent of relapsing activity, thus broadening the scope beyond traditional measures. [WATCH TIME: 4 minutes]

Radiprodil, a novel NMDA receptor modulator, demonstrated significant potential in reducing seizure frequency, with 71% of patients showing at least a 50% reduction in motor seizures.

Catch up on any of the neurology news headlines you may have missed over the course of August 2024, compiled all into one place by the NeurologyLive® team.

The global head of neurology development at Sanofi discussed the safety profile of tolebrutinib, an investigational BTK inhibitor, and how treatments like it may help transform the care for patients with multiple sclerosis. [WATCH TIME: 5 minutes]